P2X7 Receptor: the Regulator of Glioma Tumor Development and Survival

Overview

Journal Purinergic Signal

Publisher Springer

Date 2021 Dec 29

PMID 34964926

Citations 8

Authors

Damian Matysniak

Vira Chumak

Natalia Nowak

Artur Kukla

Lilya Lehka

Magdalena Oslislok

Pawel Pomorski

Affiliations

Soon will be listed here.

Abstract

P2X7 is an ionotropic nucleotide receptor, forming the cation channel upon ATP stimulation. It can also function as a large membrane pore as well as transmit ATP-dependent signal without forming a channel at all. P2X7 activity in somatic cells is well-known, but remains poorly studied in glioma tumors. The current paper presents the comprehensive study of P2X7 activity in C6 and glioma cell line showing the wide range of effects the receptor has on glioma biology. We observed that P2X7 stimulation boosts glioma cell proliferation and increases cell viability. P2X7 activation promoted cell adhesion, mitochondria depolarization, and reactive oxygen species overproduction in C6 cells. P2X7 receptor also influenced glioma tumor growth in vivo via activation of pro-survival signaling pathways and ATP release. Treatment with Brilliant Blue G, a selective P2X7 antagonist, effectively inhibited glioma tumor development; decreased the expression of negative prognostic cancer markers pro-survival and epithelial-mesenchymal transition (EMT)-related proteins; and modulated the immune response toward glioma tumor in vivo. Finally, pathway-specific enrichment analysis of the microarray data from human patients also showed an upregulation of P2X7 receptor in gliomas from grades I to III. The presented results shed more light on the role of P2X7 receptor in the biology of this disease.

Citing Articles

Role of P2X7 receptor in the progression and clinicopathological characteristics of gastric cancer.

Zhang W, Pi X, Le Y, Li T Sci Rep. 2024; 14(1):31673.

PMID: 39738256 PMC: 11685580. DOI: 10.1038/s41598-024-81515-7.

Purines and purinergic receptors in primary tumors of the central nervous system.

Soares A, Dos Santos H, Domann K, Alves N, Bohm B, Haack C Purinergic Signal. 2024; .

PMID: 39352574 DOI: 10.1007/s11302-024-10053-8.

Functional role of P2X7 purinergic receptor in cancer and cancer-related pain.

Xu Y, Xiang J, Lin S Purinergic Signal. 2024; .

PMID: 38771429 DOI: 10.1007/s11302-024-10019-w.

Machine learning discriminates P2X7-mediated intracellular calcium sparks in human-induced pluripotent stem cell-derived neural stem cells.

Hanafusa Y, Shiraishi A, Hattori F Sci Rep. 2023; 13(1):12673.

PMID: 37542080 PMC: 10403609. DOI: 10.1038/s41598-023-39846-4.

P2X7 receptor antagonism by AZ10606120 significantly reduced in vitro tumour growth in human glioblastoma.

Kan L, Drill M, Jayakrishnan P, Sequeira R, Galea E, Todaro M Sci Rep. 2023; 13(1):8435.

PMID: 37225786 PMC: 10209214. DOI: 10.1038/s41598-023-35712-5.

References

Raffaghello L, Chiozzi P, Falzoni S, Di Virgilio F, Pistoia V . The P2X7 receptor sustains the growth of human neuroblastoma cells through a substance P-dependent mechanism. Cancer Res. 2006; 66(2):907-14. DOI: 10.1158/0008-5472.CAN-05-3185. View

Ellert-Miklaszewska A, Poleszak K, Pasierbinska M, Kaminska B . Integrin Signaling in Glioma Pathogenesis: From Biology to Therapy. Int J Mol Sci. 2020; 21(3). PMC: 7037280. DOI: 10.3390/ijms21030888. View

Hambardzumyan D, Gutmann D, Kettenmann H . The role of microglia and macrophages in glioma maintenance and progression. Nat Neurosci. 2015; 19(1):20-7. PMC: 4876023. DOI: 10.1038/nn.4185. View

Chia K, Keatinge M, Mazzolini J, Sieger D . Brain tumours repurpose endogenous neuron to microglia signalling mechanisms to promote their own proliferation. Elife. 2019; 8. PMC: 6685703. DOI: 10.7554/eLife.46912. View

Morrone F, Oliveira D, Gamermann P, Stella J, Wofchuk S, Wink M . In vivo glioblastoma growth is reduced by apyrase activity in a rat glioma model. BMC Cancer. 2006; 6:226. PMC: 1592110. DOI: 10.1186/1471-2407-6-226. View

Nowicki M, Hayes J, Chiocca E, Lawler S . Proteomic Analysis Implicates Vimentin in Glioblastoma Cell Migration. Cancers (Basel). 2019; 11(4). PMC: 6521049. DOI: 10.3390/cancers11040466. View

Draganov D, Gopalakrishna-Pillai S, Chen Y, Zuckerman N, Moeller S, Wang C . Modulation of P2X4/P2X7/Pannexin-1 sensitivity to extracellular ATP via Ivermectin induces a non-apoptotic and inflammatory form of cancer cell death. Sci Rep. 2015; 5:16222. PMC: 4639773. DOI: 10.1038/srep16222. View

Kwak S, Shin S, Lee J, Shim J, Kim M, Lee S . Synthesis and structure-activity relationships of quinolinone and quinoline-based P2X7 receptor antagonists and their anti-sphere formation activities in glioblastoma cells. Eur J Med Chem. 2018; 151:462-481. DOI: 10.1016/j.ejmech.2018.03.023. View

Rueden C, Schindelin J, Hiner M, DeZonia B, Walter A, Arena E . ImageJ2: ImageJ for the next generation of scientific image data. BMC Bioinformatics. 2017; 18(1):529. PMC: 5708080. DOI: 10.1186/s12859-017-1934-z. View

10.

Adinolfi E, Giuliani A, De Marchi E, Pegoraro A, Orioli E, Di Virgilio F . The P2X7 receptor: A main player in inflammation. Biochem Pharmacol. 2017; 151:234-244. DOI: 10.1016/j.bcp.2017.12.021. View

11.

Idzko M, Ferrari D, Eltzschig H . Nucleotide signalling during inflammation. Nature. 2014; 509(7500):310-7. PMC: 4222675. DOI: 10.1038/nature13085. View

12.

Cheewatrakoolpong B, Gilchrest H, Anthes J, Greenfeder S . Identification and characterization of splice variants of the human P2X7 ATP channel. Biochem Biophys Res Commun. 2005; 332(1):17-27. DOI: 10.1016/j.bbrc.2005.04.087. View

13.

Adinolfi E, Callegari M, Ferrari D, Bolognesi C, Minelli M, Wieckowski M . Basal activation of the P2X7 ATP receptor elevates mitochondrial calcium and potential, increases cellular ATP levels, and promotes serum-independent growth. Mol Biol Cell. 2005; 16(7):3260-72. PMC: 1165409. DOI: 10.1091/mbc.e04-11-1025. View

14.

Park J, Williams D, Lee J, Lee S, Lee J, Ko H . Potent Suppressive Effects of 1-Piperidinylimidazole Based Novel P2X7 Receptor Antagonists on Cancer Cell Migration and Invasion. J Med Chem. 2016; 59(16):7410-30. DOI: 10.1021/acs.jmedchem.5b01690. View

15.

Matysniak D, Nowak N, Chumak V, Pomorski P . P2X7 receptor activity landscape in rat and human glioma cell lines. Acta Biochim Pol. 2020; 67(1):7-14. DOI: 10.18388/abp.2020_2848. View

16.

Csoka B, Nemeth Z, Toro G, Idzko M, Zech A, Koscso B . Extracellular ATP protects against sepsis through macrophage P2X7 purinergic receptors by enhancing intracellular bacterial killing. FASEB J. 2015; 29(9):3626-37. PMC: 4550379. DOI: 10.1096/fj.15-272450. View

17.

Morrone F, Gehring M, Nicoletti N . Calcium Channels and Associated Receptors in Malignant Brain Tumor Therapy. Mol Pharmacol. 2016; 90(3):403-9. DOI: 10.1124/mol.116.103770. View

18.

Gendron F, Neary J, Theiss P, Sun G, Gonzalez F, Weisman G . Mechanisms of P2X7 receptor-mediated ERK1/2 phosphorylation in human astrocytoma cells. Am J Physiol Cell Physiol. 2003; 284(2):C571-81. DOI: 10.1152/ajpcell.00286.2002. View

19.

Schultz C, Golembieski W, King D, Brown S, Brodie C, Rempel S . Inhibition of HSP27 alone or in combination with pAKT inhibition as therapeutic approaches to target SPARC-induced glioma cell survival. Mol Cancer. 2012; 11:20. PMC: 3349587. DOI: 10.1186/1476-4598-11-20. View

20.

Markovic D, Glass R, Synowitz M, van Rooijen N, Kettenmann H . Microglia stimulate the invasiveness of glioma cells by increasing the activity of metalloprotease-2. J Neuropathol Exp Neurol. 2005; 64(9):754-62. DOI: 10.1097/01.jnen.0000178445.33972.a9. View